Literature DB >> 2218158

The diagnosis of bacteriuria during pregnancy.

S Lorentzon1, B Hovelius, H Miörner, M Tendler, A Aberg.   

Abstract

Three diagnostic tests, Nitur, Urobact, and Uricult, were evaluated in the detection of bacteriuria in 865 pregnant women. As reference method agar culture was performed. Heavy growth (greater than 10(5) CFU/ml) of urinary tract bacteria was considered a true positive result and demonstrated in 58 (6.7%) of the women, 14 of whom had gram-negative rods. The sensitivity of the nitrite test was extremely low (0.13). The test gave negative results in eight of 17 specimens yielding heavy growth of Escherichia coli or Proteus mirabilis. Although the Urobact test was highly sensitive as regards gram-negative infection, it had an unacceptably low (0.27) predictive value in positive tests. The sensitivity of the Uricult test was low (0.35) in this study. The predictive value (0.50) of a positive test result may be acceptable, since just over half of the false positive results were explainable by moderate growth of urinary tract pathogens (10(4)-10(5) CFU/ml). It is argued that semi-quantitative urine culture may be preferable to the rapid diagnostic methods studied for the screening of bacteriuria in pregnant women.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2218158     DOI: 10.3109/02813439008994935

Source DB:  PubMed          Journal:  Scand J Prim Health Care        ISSN: 0281-3432            Impact factor:   2.581


  2 in total

Review 1.  Benefits and harms of screening for and treatment of asymptomatic bacteriuria in pregnancy: a systematic review.

Authors:  Konstanze Angelescu; Barbara Nussbaumer-Streit; Wiebke Sieben; Fülöp Scheibler; Gerald Gartlehner
Journal:  BMC Pregnancy Childbirth       Date:  2016-11-02       Impact factor: 3.007

Review 2.  The urine dipstick test useful to rule out infections. A meta-analysis of the accuracy.

Authors:  Walter L J M Devillé; Joris C Yzermans; Nico P van Duijn; P Dick Bezemer; Daniëlle A W M van der Windt; Lex M Bouter
Journal:  BMC Urol       Date:  2004-06-02       Impact factor: 2.264

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.